Patent Granted to Cesca Therapeutics Inc (NASDAQ:KOOL) Subsidiary

Cesca Therapeutics Inc (NASDAQ:KOOL)

Cesca Therapeutics Inc (NASDAQ:KOOL)

Cesca Therapeutics Inc (NASDAQ:KOOL) shares are up almost 10%. The gain is due to the market’s reaction of a patent award to SynGen – a company that had sold its processing assets to Thermogenics which is 80% owned by Cesca. The patent for “Cell Separation Devices, Systems, and Methods” was awarded on July 10, 2017 and is known as U.S. Patent, No. 9,695,394. Shares of Cesca Therapeutics Inc (NASDAQ:KOOL) are normally thinly traded – about 38,000 per day, on average. However by 12:30 PM EST, over 2.8 million shares have traded hands.

Cesca Therapeutics Inc (NASDAQ:KOOL)
One month daily candlebar graph for $KOOL

The patent relates to the automated isolation of rare, therapeutically critical target cells from blood, bone marrow, leukapheresis product, and other cell sources, while maintaining the viability of the cells under asceptic conditions. Chris Xu, Cesca’s CEO, stated in a press release “This new patent issuance significantly strengthens the intellectual property position surrounding our proprietary automation technology which is core to our best-in-class ThermoGenesis portfolio of cell processing systems.”

Cesca Therapeutics Inc (NASDAQ:KOOL), headquartered in Rancho Cordova, CA, develops, commercializes, and markets technologies for cell-based therapeutics. ThermoGenesis is Cesca’s device division It provides solutions for automated clinical biobanking, point-of-care applications, and automation for immuno-oncology.

Shareholders of Cesca Therapeutics Inc (NASDAQ:KOOL) have experienced large losses every year since 2012 when the company posted a per share loss of (-$6.09). That loss was followed by annual, per share losses of (-$3.74), (-$7.12), (-$7.36), and, in 2016, (-$7.57). Unfortunately, sales have been trending downwards. In 2012 sales were $19 million, followed by annual sales of $18 million, $16 million, $16 million, and $11.9 million in 2016. Outstanding shares have been on the uptrend – seriously diluting shareholder equity. 830,000 shares were outstanding in 2013. That number increased every year and was listed at 2.46 million by the end of 2016.

The sole firm that follows Cesca Therapeutics Inc (NASDAQ:KOOL) rates the shares as a “Hold”.

I have no positions in any of the stocks mentioned, and have no plans to initiate any positions within the next 72 hours. All information, including any data, is provided without any guarantees of accuracy.

Don’t miss out! Stay informed on $KOOL and receive breaking news on other hot stocks by signing up for our free newsletter!

About the author: Marc has a degree in economics and a MSc. in Finance. Over his 20-year career, Marc has worked for global investment firms in Europe and the United States as an analyst, fund manager, and consultant.

Author: Marcus Anderson

Marc has a degree in economics and a MSc. in Finance. Marc worked for global investment firms in Europe and the United States as an analyst, fund manager, and consultant.

Leave a Reply

Your email address will not be published. Required fields are marked *